How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?
Onglyza in the real world: No increased risk of hospitalisation for heart failure relative to sitagliptin
Hospitalisation for heart failure hazard ratios for Onglyza relative to sitagliptin1,2
An observational cohort study from a US claims database showed that there was no statistically significant difference in the hazards of hospitalisation for heart failure between Onglyza-versus sitagliptin-treated patients.
1. Fu AZ et al. Diabetes Care 2016; 39: 726-734.
2. Fu AZ et al. Risk of hopitalization for heart failure with dipeptidyl peptidase-4 inhibitors vs. sulfonylureas and with saxagliptin vs. sitagliptin in a U.S. claims database. Presented at the American Diabetes Association 75th Scientific Sessions, Boston, MA, 5-9 June 2015.